MOLN: MP0712 leads a radiotherapeutics pivot, with cash runway into late 2027Quartr·Oct 29, 2026 at 10:06 AMMOLN+1.42%
Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy | MOLN Stock NewsStockTitan·Oct 28, 2026 at 10:00 PMMOLN+1.42%
Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70 | MOLN Stock NewsStockTitan·Oct 21, 2026 at 09:00 PMMOLN+1.42%
Molecular Partners AG Stock 12‑Month Price Target Raised to $11.24, Implies 195% UpsideTradingView·Oct 9, 2026 at 07:20 AMMOLN+1.42%
European Hidden Gems: Lhyfe And 2 Other Promising Penny StocksSimplywall·Sep 21, 2026 at 06:01 AMMOLN+1.42%
Molecular Partners: Pipeline Momentum and Early Safety Data Support Unchanged $12 Price Target and Buy RatingTip Ranks·Aug 25, 2026 at 08:15 PMMOLN+1.42%
MOLN: MP0712 advances in SCLC trials, CD70 program announced, and cash runway extends into late 2027Quartr·Aug 25, 2026 at 07:21 AMMOLN+1.42%
MOLN: Cash of CHF 68M supports advancing DARPin oncology pipeline, with key data expected in 2026Quartr·Aug 25, 2026 at 05:12 AMMOLN+1.42%
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study | MOLN Stock NewsStockTitan·Aug 24, 2026 at 09:00 PMMOLN+1.42%
Molecular Partners H1 FY26 net loss narrows to CHF 26.7 million; operating loss improves to CHF 27 millionPUBT·Aug 25, 2026 at 05:00 AMMOLN+1.42%
